News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
440,022 Results
Type
Article (24502)
Company Profile (144)
Press Release (415370)
Multimedia
Podcasts (107)
Webinars (17)
Section
Business (131777)
Career Advice (933)
Deals (23056)
Drug Delivery (103)
Drug Development (61076)
Employer Resources (82)
FDA (9681)
Job Trends (9519)
News (228592)
Policy (20439)
Tag
Academia (1149)
Accelerated approval (12)
Adcomms (23)
Allergies (89)
Alliances (31078)
ALS (103)
Alzheimer's disease (1113)
Antibody-drug conjugate (ADC) (209)
Approvals (9827)
Artificial intelligence (331)
Autoimmune disease (69)
Automation (17)
Bankruptcy (211)
Best Places to Work (7258)
BIOSECURE Act (14)
Biosimilars (149)
Biotechnology (60)
Bladder cancer (113)
Brain cancer (38)
Breast cancer (372)
Cancer (3092)
Cardiovascular disease (261)
Career advice (771)
Career pathing (22)
CAR-T (126)
CDC (14)
Cell therapy (376)
Cervical cancer (26)
Clinical research (52998)
Collaboration (1064)
Company closure (1)
Compensation (534)
Complete response letters (46)
COVID-19 (1380)
CRISPR (53)
C-suite (454)
Cystic fibrosis (102)
Data (3795)
Decentralized trials (2)
Denatured (25)
Depression (71)
Diabetes (301)
Diagnostics (3097)
Digital health (25)
Diversity (9)
Diversity, equity & inclusion (23)
Drug discovery (153)
Drug pricing (175)
Drug shortages (33)
Duchenne muscular dystrophy (151)
Earnings (59679)
Editorial (43)
Employer branding (10)
Employer resources (80)
Events (77874)
Executive appointments (756)
FDA (11472)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (6)
Funding (829)
Gene editing (110)
Generative AI (27)
Gene therapy (337)
GLP-1 (798)
Government (2565)
Grass and pollen (7)
Guidances (294)
Healthcare (9390)
HIV (37)
Huntington's disease (28)
IgA nephropathy (55)
Immunology and inflammation (175)
Immuno-oncology (15)
Indications (49)
Infectious disease (1537)
Inflammatory bowel disease (137)
Inflation Reduction Act (13)
Influenza (54)
Intellectual property (136)
Interviews (128)
IPO (10463)
IRA (52)
Job creations (2592)
Job search strategy (682)
Kidney cancer (13)
Labor market (55)
Layoffs (360)
Leadership (27)
Legal (4730)
Liver cancer (65)
Longevity (8)
Lung cancer (502)
Lymphoma (214)
Machine learning (24)
Management (32)
Manufacturing (482)
MASH (106)
Medical device (5024)
Medtech (5035)
Mergers & acquisitions (13251)
Metabolic disorders (863)
Multiple sclerosis (109)
NASH (22)
Neurodegenerative disease (157)
Neuropsychiatric disorders (46)
Neuroscience (1883)
NextGen: Class of 2025 (3211)
Non-profit (1654)
Now hiring (42)
Obesity (453)
Opinion (228)
Ovarian cancer (97)
Pain (139)
Pancreatic cancer (129)
Parkinson's disease (184)
Partnered (15)
Patents (292)
Patient recruitment (230)
Peanut (33)
People (38383)
Pharmaceutical (77)
Pharmacy benefit managers (29)
Phase I (16038)
Phase II (22730)
Phase III (18272)
Pipeline (2159)
Policy (213)
Postmarket research (1939)
Preclinical (6173)
Press Release (33)
Prostate cancer (167)
Psychedelics (28)
Radiopharmaceuticals (205)
Rare diseases (494)
Real estate (3574)
Recruiting (33)
Regulatory (15609)
Reports (28)
Research institute (1208)
Resumes & cover letters (150)
Rett syndrome (11)
RNA editing (8)
RSV (50)
Schizophrenia (118)
Series A (139)
Series B (97)
Service/supplier (9)
Sickle cell disease (65)
Special edition (23)
Spinal muscular atrophy (121)
Sponsored (18)
Startups (2227)
State (2)
Stomach cancer (15)
Supply chain (84)
Tariffs (93)
The Weekly (80)
Vaccines (497)
Venture capital (52)
Weight loss (334)
Women's health (34)
Worklife (8)
Date
Today (148)
Last 7 days (580)
Last 30 days (2084)
Last 365 days (23527)
2025 (19522)
2024 (24349)
2023 (26258)
2022 (33510)
2021 (34903)
2020 (32714)
2019 (26562)
2018 (20462)
2017 (21282)
2016 (20272)
2015 (23858)
2014 (18786)
2013 (15384)
2012 (16573)
2011 (17209)
2010 (15682)
Location
Africa (453)
Alabama (48)
Alaska (2)
Arizona (118)
Arkansas (10)
Asia (29029)
Australia (4156)
California (6726)
Canada (2077)
China (734)
Colorado (274)
Connecticut (309)
Delaware (236)
Europe (63075)
Florida (963)
Georgia (174)
Hawaii (2)
Idaho (23)
Illinois (541)
India (46)
Indiana (332)
Iowa (9)
Japan (304)
Kansas (83)
Kentucky (29)
Louisiana (7)
Maine (25)
Maryland (821)
Massachusetts (5199)
Michigan (137)
Minnesota (336)
Mississippi (3)
Missouri (94)
Montana (13)
Nebraska (12)
Nevada (68)
New Hampshire (25)
New Jersey (2063)
New Mexico (23)
New York (1780)
North Carolina (869)
North Dakota (4)
Northern California (3099)
Ohio (177)
Oklahoma (12)
Oregon (24)
Pennsylvania (1299)
Puerto Rico (18)
Rhode Island (27)
South America (677)
South Carolina (12)
Southern California (2657)
Tennessee (91)
Texas (1002)
United States (24226)
Utah (164)
Virginia (206)
Washington D.C. (67)
Washington State (577)
West Virginia (2)
Wisconsin (75)
440,022 Results for "purdue pharma l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.
March 27, 2024
·
7 min read
Press Releases
L7 Informatics Challenges the ELN Replacement Cycle in Pharma and Biotech
September 25, 2025
·
1 min read
L7 Informatics Named Top Innovator in 2025 Frost & Sullivan Frost Radar™ for Pharma and Biotech LIMS
October 31, 2025
·
3 min read
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
5 SMID-Cap Pharmas Poised for M&A Action
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to mid-cap pharmas best prepared to bolster their pipelines with a buyout.
October 29, 2025
·
7 min read
·
Annalee Armstrong
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
·
4 min read
·
Annalee Armstrong
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.
October 1, 2025
·
4 min read
·
Nick Paul Taylor
Tariffs
Trump Delays Pharma Tariffs Yet Again
President Donald Trump last week announced that 100% pharma tariffs would come Oct. 1, but a White House official has clarified that that’s when the government will “begin preparing” the levies.
October 2, 2025
·
2 min read
·
Tristan Manalac
Policy
NHS Mulls Greater Pharma Spending to Head Off Trump’s Tariffs: Report
The British proposal to increase support for pharma is “clearly positive,” according to analysts at Leerink, who noted that the NHS’ move will improve patient access to treatments.
October 10, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
The Top Big Pharmas Have $1.2T in Stretch M&A Firepower Available
The two most historically deal-conservative Big Pharmas have the most money to play with for a major M&A transaction, according to a recent Stifel analysis.
October 1, 2025
·
6 min read
·
Annalee Armstrong
1 of 44,003
Next
